Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Eylea

Eylea 114.3 mg/ml solution for injection Eylea 114.3 mg/ml solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 69–70

HOS-125721 · Präparat HOS-096119

69 Table 1: All treatment-emergent adverse reactions reported in patients with nAMD, DME or RVO treated with Eylea 114.3 mg/ml in phase II/III studies or during post-marketing surveillance System organ class Frequency Adverse reaction Immune system Common Hypersensitivity* disorders Eye disorders Common Cataract, Intraocular pressure increased, Vitreous floaters, Vitreous detachment, Vitreous haemorrhage, Retinal haemorrhage, Visual acuity reduced, Eye pain, Conjunctival haemorrhage, Punctate keratitis, Corneal abrasion Uncommon Retinal detachment, Retinal tear, Retinal pigment epithelial tear, Detachment of the retinal pigment epithelium, Uveitis, Iritis, Iridocyclitis, Vitritis, Cataract cortical, Cataract nuclear, Cataract subcapsular, Corneal erosion, Vision blurred, Injection site pain, Foreign body sensation in eyes, Lacrimation increased, Injection site haemorrhage, Conjunctival hyperaemia, Lenticular opacities, Eyelid oedema, Ocular hyperaemia, Injection site irritation, Retinal degeneration, Corneal oedema Rare Blindness, Endophthalmitis, Eyelid irritation, Retinal vasculitis Not known Scleritis**, Retinal occlusive vasculitis** * Reports of hypersensitivity included rash, pruritus, urticaria. ** From post-marketing reporting.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.